These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9824113)

  • 1. p53 gene mutations in osteosarcomas of low-grade malignancy.
    Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
    Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation spectrum of p53 gene in highly malignant human osteosarcomas.
    Radig K; Schneider-Stock R; Oda Y; Neumann W; Mittler U; Roessner A
    Gen Diagn Pathol; 1996 Jun; 142(1):25-32. PubMed ID: 8793483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
    Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
    Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
    Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
    Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.
    Gokgoz N; Wunder JS; Mousses S; Eskandarian S; Bell RS; Andrulis IL
    Cancer; 2001 Oct; 92(8):2181-9. PubMed ID: 11596036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.
    Johnson AS; Couto CG; Weghorst CM
    Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 gene mutations in osteosarcomas in the dog.
    van Leeuwen IS; Cornelisse CJ; Misdorp W; Goedegebuure SA; Kirpensteijn J; Rutteman GR
    Cancer Lett; 1997 Jan; 111(1-2):173-8. PubMed ID: 9022143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?
    Taubert H; Berger D; Hinze R; Meye A; Würl P; Hogendoorn PC; Holzhausen HJ; Schmidt H; Rath FW
    Cancer Lett; 1998 Jan; 123(2):147-51. PubMed ID: 9489481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and ras mutations in Ewing's sarcoma.
    Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
    Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPS3 amplification and clinical outcome in osteosarcoma.
    Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
    Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters.
    Oliveira CR; Mendonça BB; Camargo OP; Pinto EM; Nascimento SA; Latorre Mdo R; Zerbini MC
    Clinics (Sao Paulo); 2007 Apr; 62(2):167-74. PubMed ID: 17505702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.
    Salinas-Souza C; De Andrea C; Bihl M; Kovac M; Pillay N; Forshew T; Gutteridge A; Ye H; Amary MF; Tirabosco R; Toledo SR; Baumhoer D; Flanagan AM
    Mod Pathol; 2015 Oct; 28(10):1336-42. PubMed ID: 26248895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.
    Grote HJ; Schneider-Stock R; Neumann W; Roessner A
    Virchows Arch; 2000 May; 436(5):494-7. PubMed ID: 10881744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
    Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
    J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
    J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytogenetic changes in low grade central osteosarcomas].
    Werner M; Rieck J; Delling G
    Verh Dtsch Ges Pathol; 1998; 82():189-94. PubMed ID: 10095432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
    Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
    Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.